The AMA Code of Ethics articulates and promotes a body of ethical principles to guide doctors' conduct in their relationships with patients, colleagues and society. This Code has grown out of other similar ethical codes stretching back into history including the Hippocratic Oath.
All individuals have the right to make their own decisions about reproduction and the use of available reproductive medicine. Reproductive medicine includes services to manage fertility, such as family planning services, as well as infertility, including assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), artificial insemination, and various methods of ovulation induction.
This position statement outlines general principles required for an effective system of follow-up, recall and reminders. It highlights the role of communication and consent within the doctor-patient relationship and attempts to strike a reasonable balance between the responsibilities of doctors and those of patients.
Doctors (medical practitioners) are entitled to have their own personal beliefs and values, as are all members of society. There may be times, however, where a doctor’s personal beliefs conflict with their peer-based professional practice. A doctor who makes a conscientious objection to providing, or participating, in certain treatments or procedures should make every effort in a timely manner to minimise the disruption in the delivery of health care and ensuing burden on colleagues. The doctor needs to take whatever steps are necessary to ensure the patient's access to care is not impeded.
The AMA has made the following submission to the Generics Medicine Industry Association in response to the draft 3rd edition of its Code of Practice.
The AMA supports increased transparency measures in addition to those already voluntarily undertaken by Medicines Australia. However it is critical that careful thought is given to the development of a model for reporting industry payments to individual practitioners. A successful reporting model should provide information to enable patients to make informed decisions about their healthcare options taking into account the context and nature of their practitioner's involvement with companies.
Each State and Territory has laws regulating t
Members may have recently received a notice ad
The AMA has made the following submission to the Senate Inquiry into the Therapeutic Goods Amendment (Pharmaceutical Transparency) Bill 2013.
Many members have recently received what we un
- 1 of 13